These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31626293)

  • 41. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.
    Ilieva NM; Hoffman EK; Ghalib MA; Greenamyre JT; De Miranda BR
    Neurobiol Dis; 2024 Jun; 196():106522. PubMed ID: 38705492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila.
    Marcogliese PC; Abuaish S; Kabbach G; Abdel-Messih E; Seang S; Li G; Slack RS; Haque ME; Venderova K; Park DS
    Hum Mol Genet; 2017 Apr; 26(7):1247-1257. PubMed ID: 28158614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia.
    Mamais A; Kluss JH; Bonet-Ponce L; Landeck N; Langston RG; Smith N; Beilina A; Kaganovich A; Ghosh MC; Pellegrini L; Kumaran R; Papazoglou I; Heaton GR; Bandopadhyay R; Maio N; Kim C; LaVoie MJ; Gershlick DC; Cookson MR
    PLoS Biol; 2021 Dec; 19(12):e3001480. PubMed ID: 34914695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LRRK2 mediates axon development by regulating Frizzled3 phosphorylation and growth cone-growth cone communication.
    Onishi K; Tian R; Feng B; Liu Y; Wang J; Li Y; Zou Y
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18037-18048. PubMed ID: 32641508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model.
    Jia R; Liu Y; Shuai K; Zhou C; Chen L; Zhu L; Wu XM
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
    Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
    Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LRRK2 Gly2019Ser Mutation Promotes ER Stress via Interacting with THBS1/TGF-β1 in Parkinson's Disease.
    Yao L; Lu F; Koc S; Zheng Z; Wang B; Zhang S; Skutella T; Lu G
    Adv Sci (Weinh); 2023 Oct; 10(30):e2303711. PubMed ID: 37672887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.
    Walter J; Bolognin S; Antony PMA; Nickels SL; Poovathingal SK; Salamanca L; Magni S; Perfeito R; Hoel F; Qing X; Jarazo J; Arias-Fuenzalida J; Ignac T; Monzel AS; Gonzalez-Cano L; Pereira de Almeida L; Skupin A; Tronstad KJ; Schwamborn JC
    Stem Cell Reports; 2019 May; 12(5):878-889. PubMed ID: 30982740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.
    Borgs L; Peyre E; Alix P; Hanon K; Grobarczyk B; Godin JD; Purnelle A; Krusy N; Maquet P; Lefebvre P; Seutin V; Malgrange B; Nguyen L
    Sci Rep; 2016 Sep; 6():33377. PubMed ID: 27640816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
    Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
    Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.